3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Monoamino oxidase alleles correlate with the presence of essential hypertension among hypogonadic patients

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Monoamine oxidase (MAO) activity has been traditionally implicated in blood pressure through its effects on biogenic amine levels such as catecholamines, serotonin, and dopamine. Nowadays, this role is considered relegated to side‐effects such as orthostatic hypotension and/or hypertensive crisis derived from MAO‐inhibitory treatments in patients with psychiatric disease.

          Methods

          In the present work we have found an association between a polymorphic variant of MAOB gene and arterial hypertension in obese hypogonadic patients. The study cases comprised a series of 219 nondiabetic males with a body mass index ≥30 kg/m 2 and aged <45 years. Hypogonadism was defined as subnormal testosterone concentrations, when free testosterone values ranged <65 pg/ml.

          Results

          MAOB rs3027452‐A allele carriers were significantly over‐represented among hypertensive (HT) patients (25.49%) in comparison to either the non‐HT patients (10%, OR = 3.079 CI 95 [1.364–6.952], p = .005, Chi‐square test) and the control population series of nonobese nor hypogonadic males (also 10%, p = .003 Chi‐square test). Upon adjusted, an independent association was shown with the hypogonadic group with hypertension when compared with nonhypertensive hypogonadics (Beta = 3.653, p = .005). When quantitative analysis was performed, hypertensive patients harboring rs3027452‐A allele showed higher systolic blood pressure values ( p = .038, Mann–Whitney U‐test) as well as an increased Systolic‐Diastolic range despite following HT treatment (∆mmHg 54 vs. 48 for rs3027452‐A and rs3027452‐G respectively, p‐value .019, Mann–Whitney U‐test). Previous studies on MAOB revealed that rs3027452‐A allele has been correlated to a lower activity of the enzyme, what gives a functional evidence over our observation.

          Conclusion

          If this result could be extrapolated to other hypertensive patient groups, it would implicate a review of the markers and therapeutic targets on human hypertension.

          Abstract

          Male hypogonadism is a disorder in which the testes are not functional or there is a genetic inability of the hypothalamus to secrete normal amounts of GnRH. The masculine sexual characteristics are not developed and can bring a wide range of clinical manifestations. We have found an association between a polymorphic variant of MAOB gene and arterial hypertension in obese hypogonadic patients.

          Related collections

          Most cited references61

          • Record: found
          • Abstract: not found
          • Article: not found

          The serotonin syndrome.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.

            A few years after the foundation of the British Pharmacological Society, monoamine oxidase (MAO) was recognized as an enzyme of crucial interest to pharmacologists because it catalyzed the major inactivation pathway for the catecholamine neurotransmitters, noradrenaline, adrenaline and dopamine (and, later, 5-hydroxytryptamine, as well). Within the next decade, the therapeutic value of inhibitors of MAO in the treatment of depressive illness was established. Although this first clinical use exposed serious side effects, pharmacological interest in, and investigation of, MAO continued, resulting in the characterization of two isoforms, MAO-A and -B, and isoform-selective inhibitors. Selective inhibitors of MAO-B have found a therapeutic role in the treatment of Parkinson's disease and further developments have provided reversible inhibitors of MAO-A, which offer antidepressant activity without the serious side effects of the earlier inhibitors. Clinical observation and subsequent pharmacological analysis have also generated the concept of neuroprotection, reflecting the possibility of slowing, halting and maybe reversing, neurodegeneration in Parkinson's or Alzheimer's diseases. Increased levels of oxidative stress in the brain may be critical for the initiation and progress of neurodegeneration and selective inhibition of brain MAO could contribute importantly to lowering such stress. There are complex interactions between free iron levels in brain and MAO, which may have practical outcomes for depressive disorders. These aspects of MAO and its inhibition and some indication of how this important area of pharmacology and therapeutics might develop in the future are summarized in this review.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Serotonin and blood pressure regulation.

              5-Hydroxytryptamine (5-HT; serotonin) was discovered more than 60 years ago as a substance isolated from blood. The neural effects of 5-HT have been well investigated and understood, thanks in part to the pharmacological tools available to dissect the serotonergic system and the development of the frequently prescribed selective serotonin-reuptake inhibitors. By contrast, our understanding of the role of 5-HT in the control and modification of blood pressure pales in comparison. Here we focus on the role of 5-HT in systemic blood pressure control. This review provides an in-depth study of the function and pharmacology of 5-HT in those tissues that can modify blood pressure (blood, vasculature, heart, adrenal gland, kidney, brain), with a focus on the autonomic nervous system that includes mechanisms of action and pharmacology of 5-HT within each system. We compare the change in blood pressure produced in different species by short- and long-term administration of 5-HT or selective serotonin receptor agonists. To further our understanding of the mechanisms through which 5-HT modifies blood pressure, we also describe the blood pressure effects of commonly used drugs that modify the actions of 5-HT. The pharmacology and physiological actions of 5-HT in modifying blood pressure are important, given its involvement in circulatory shock, orthostatic hypotension, serotonin syndrome and hypertension.
                Bookmark

                Author and article information

                Contributors
                fjtinahones@hotmail.com
                josecarlosfdezgarcia@hotmail.com
                Journal
                Mol Genet Genomic Med
                Mol Genet Genomic Med
                10.1002/(ISSN)2324-9269
                MGG3
                Molecular Genetics & Genomic Medicine
                John Wiley and Sons Inc. (Hoboken )
                2324-9269
                19 November 2019
                January 2020
                : 8
                : 1 ( doiID: 10.1002/mgg3.v8.1 )
                : e1040
                Affiliations
                [ 1 ] Department of Surgery, Biochemistry and Immunology School of Medicine University of Malaga Málaga Spain
                [ 2 ] Unidad de Gestión Clínica de Endocrinología y Nutrición del Hospital Virgen de la Victoria Instituto de Investigación Biomédica de Málaga (IBIMA) Universidad de Málaga Málaga Spain
                [ 3 ] Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición, CIBERobn Málaga Spain
                Author notes
                [*] [* ] Correspondence

                José C. Fernández‐García and Francisco J. Tinahones, Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Campus de Teatinos s/n, Málaga 29010, Spain.

                Email: josecarlosfdezgarcia@ 123456hotmail.com (J. C. F.‐G.) and fjtinahones@ 123456hotmail.com (F. J. T.)

                Author information
                https://orcid.org/0000-0003-2024-4363
                Article
                MGG31040
                10.1002/mgg3.1040
                6978270
                31743621
                5f425b72-87cc-4fa6-8157-7eb5daa52ee4
                © 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 12 March 2019
                : 04 October 2019
                : 11 October 2019
                Page count
                Figures: 1, Tables: 3, Pages: 8, Words: 5796
                Funding
                Funded by: Andalusian Health Public System
                Award ID: PI‐0173‐2013
                Award ID: B‐0003‐2017
                Funded by: Fondo Europeo de Desarrollo Regional ‐ FEDER
                Award ID: C‐0032‐2016
                Funded by: Ministerio de Educación, Cultura y Deporte , open-funder-registry 10.13039/501100003176;
                Award ID: FPU13/04211
                Categories
                Original Article
                Original Articles
                Custom metadata
                2.0
                January 2020
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.5 mode:remove_FC converted:23.01.2020

                hypertension,hypogonadism,maoa,maob
                hypertension, hypogonadism, maoa, maob

                Comments

                Comment on this article